PROVENGE Drug Profile

Summary for Tradename: PROVENGE

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for PROVENGE

Recent Clinical Trials for PROVENGE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yale University	Phase 2
Dendreon	Phase 3
H. Lee Moffitt Cancer Center and Research Institute	Phase 2

See all PROVENGE clinical trials

Pharmacology for PROVENGE

Physiological Effect	Cell-mediated Immunity
Established Pharmacologic Class	Autologous Cellular Immunotherapy
Chemical Structure	Leukocytes, Mononuclear

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROVENGE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROVENGE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	5,976,546	2018-09-03	DrugPatentWatch analysis and company disclosures
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	6,210,662	2019-06-24	DrugPatentWatch analysis and company disclosures
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	7,413,869	2022-04-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PROVENGE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	10,071,953	2036-01-12	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	10,196,695	2034-12-01	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	10,196,696	2034-12-01	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	10,196,697	2034-12-12	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197	10,232,051	2037-03-03	Patent claims search

Market Dynamics and Financial Trajectory for PROVENGE (Sipuleucel-T)

Last updated: April 13, 2026

What is PROVENGE and How Is It Positioned in the Market?

PROVENGE (sipuleucel-T) is an autologous cellular immunotherapy approved by the FDA in 2010 for treating asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Produced by Dendreon, it is designed to stimulate the patient’s immune system to target prostate cancer cells.

Distinctive Features:

• First FDA-approved autologous cellular therapy.
• Uses patient's own immune cells activated ex vivo.
• Indicated for certain prostate cancer patients with limited options.

Market Size and Target Population:

• Global prostate cancer market approximates $20 billion in 2022.
• mCRPC accounts for nearly 30% of prostate cancer cases.
• Estimated eligible patient population stands at roughly 35,000–40,000 annually in the U.S.

How Has PROVENGE Performed Commercially Since Approval?

Sales Dynamics:

• Peak sales in 2014 reached approximately $303 million.
• Revenue declined to $95 million in 2020 amid market competition and reimbursement challenges.
• Dendreon filed for bankruptcy in 2014, then was acquired by Vogel Capital for $82 million and relisted on NASDAQ in 2016.

Reimbursement and Adoption Challenges:

• Reimbursement hurdles, including high manufacturing costs and complex administration processes.
• Compared to androgen receptor pathway inhibitors (e.g., abiraterone, enzalutamide), which are oral and administered more conveniently, PROVENGE’s usage remains limited.
• Physician preference and patient awareness influence uptake.

Competitive Landscape and Market Dynamics

Competitive agents:

• Oral therapies like abiraterone (Zytiga), enzalutamide (Xtandi).
• Chemotherapy options such as docetaxel.
• Other immunotherapies in development.

Impact of Competition:

• Oral agents offer convenience and broader applicability.
• Increased survival benefits with combination therapies reduce the relative advantage of PROVENGE.
• Market share for PROVENGE has declined from early dominance.

Emerging Trends:

• Personalized immunotherapy advances.
• Biomarkers facilitating better patient selection.
• Regulatory incentives pushing innovation in prostate cancer immunotherapies.

Financial Trajectory and Outlook

Revenue Projections:	Year	Revenue (USD millions)	Growth/Decline (%)
2016	57	N/A
2017	76	+33%
2018	90	+18.4%
2019	94	+4.4%
2020	95	+1.0%
2021	92	-3.2%

Market Drivers:

• Ongoing clinical trials exploring combination regimens.
• Increasing adoption in select clinics, especially within academic centers.
• Potential expansion of indications and combination strategies.

Risks:

• Reimbursement pressures.
• Competition from newer immunotherapies and oral agents.
• Manufacturing complexity influencing margins.

Strategic Considerations for Stakeholders

Manufacturers:

• Optimize manufacturing efficiency to reduce costs.
• Invest in clinical trials to establish comparative efficacy.
• Develop partnerships with payers to improve reimbursement.

Investors:

• Monitor revenue trends and pipeline developments.
• Evaluate market share erosion risks due to competition.
• Watch for regulatory updates that could expand or limit usage.

Key Takeaways

• PROVENGE remains a niche treatment, with sales declining amid stiff competition and reimbursement obstacles.
• The evolving prostate cancer treatment landscape favors oral agents and combination regimens.
• Future growth depends on clinical breakthroughs, strategic manufacturing, and reimbursement negotiations.

FAQs

1. What limits PROVENGE’s market penetration?

Manufacturing complexity, high costs, reimbursement challenges, and competition from oral therapies.

2. Are there ongoing efforts to expand PROVENGE’s indications?

Yes, clinical trials explore combination therapies and biomarker-driven patient selection, but no new indications approved as of 2023.

3. How does PROVENGE compare cost-wise to its rivals?

Treatment cost exceeds $93,000 per course, compared to oral therapies costing approximately $4,000–$7,000 annually.

4. What are the prospects for PROVENGE’s future sales?

Limited without breakthroughs in efficacy, cost reduction, or expanded indications; potential growth hinges on innovations in immunotherapy.

5. What is the significance of clinical trials involving PROVENGE?

Successful trials could improve positioning against competitors and justify broader adoption. Conversely, negative results may accelerate decline.

References

[1] National Cancer Institute. (2022). Prostate Cancer Treatments. https://www.cancer.gov/types/prostate/research

[2] Dendreon. (2021). PROVENGE (sipuleucel-T) Prescribing Information.

[3] IQVIA. (2022). Prostate Cancer Market Data. https://www.iqvia.com

[4] U.S. Food & Drug Administration. (2010). FDA Approves Provenge to Treat Prostate Cancer. https://www.fda.gov